Quantum Pharmaceuticals
Quantum Pharmaceuticals is a technology based drug discovery company. We develop a unique computational drug discovery platform (QUANTUM), provide drug discovery services, and pursue our own in-house drug discovery projects searching for novel compounds with anti-bacterial, anti-viral and anti-cancer efficacy.
Quantum@linkedin.com
Contacts: office@q-pharm.com or comment any post on the site. You are welcome!Categories
- absorbtion (3)
- active transport (2)
- ADME (4)
- antibiotics (2)
- antiviral (6)
- bioavailability (3)
- cancer (5)
- cardiotoxicity (1)
- collaboration (14)
- compound libraries (1)
- COPD (1)
- docking (13)
- drug design (9)
- drug discovery platform (1)
- druglikeness (4)
- false positive (3)
- flue (4)
- Generalized Born (15)
- GPCR (1)
- HERG (6)
- HIV (4)
- HIV-1 integrase (1)
- HSV (1)
- human neutrophil elastase (1)
- IC50 (18)
- inflammation (3)
- influenza (3)
- kinase (1)
- LD50 (2)
- logP (1)
- matrix proteins (3)
- mechanism of action exploration (2)
- MRDD (3)
- new therapeutic uses (1)
- oncology (4)
- openbabel (3)
- PDK1 (1)
- polar liquid (17)
- publications (12)
- q-Mol (1)
- QSAR (1)
- Quantum Software (11)
- RecA (1)
- scoring (1)
- selectivity (3)
- solvation energy (19)
- ss DNA (1)
- talk (5)
- toxicity (7)
- trombine (2)
- tuberculosis (4)
- Uncategorized (6)
- video (3)
- water (20)
Recent comments
- anith on Free energy perturbation theory for accurate IC50 calculations
- Vladimir Chupakhin on Solubility in water/DMSO prediction
- Nbarnes25 on Services
- New MA/p17 matrix protein inhibitors display broad antiviral activity against multiple subtypes of HIV-1 on Influenza matrix M1 protein inhibitors show promising in-vivo efficacy
- Anonymous on Water polarization and density profiles at a gas-liquid interface
matrix proteins Archive
-
Development of a small-molecule antiviral targeting the HIV-1 matrix protein
Posted on March 28, 2013 | No CommentsDue to the emergence of drug-resistant strains and the cumulative toxicities associated with current therapies, demand remains for new inhibitors of HIV-1 replication. The HIV-1 matrix (MA) protein is an... -
New MA/p17 matrix protein inhibitors display broad antiviral activity against multiple subtypes of HIV-1
Posted on June 21, 2011 | No CommentsA key issue in the development of novel HIV drugs is their ability to inhibit the replication of genetically diverse isolates, especially those isolates from the most globally prevalent subtypes,... -
Influenza matrix M1 protein inhibitors show promising in-vivo efficacy
Posted on April 10, 2011 | 1 CommentWe have recently reported a discovery of novel potent inhibitors of influenza M1 matrix protein. The matrix protein structurally forms the protein envelope and has no close human analogues. That’s...